Bora Pharmaceuticals https://validator.w3.org/feed/docs/rss2.html 功能性委員會 Careers Functional Committee 投資人專區總覽 Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract Every Action for Sustainability is a Force for Change Shareholder Services 股東服務 IR Desk Reports and Presentations 財報與季度營運報告 領導團隊 Leadership 人才吸引與留任 氣候與能源 ADR Program Stock Quote and Share Information 保瑞藥業與GlaxoSmithKline 續約為期五年、總額2.5億美元之全球製造合約 Cybersecurity 每一個永續行動，都是改變地球的力量 社會公益 企業永續管理架構 重大性議題識別 Material Topics Identification 保瑞藥業中壢廠核准登記為保稅工廠　期供應鏈效率再躍進 Bora Pharmaceuticals’ Zhongli Facility Approved as a Bonded Factory, Advancing Supply Chain Efficiency TWi-企業永續發展自評表 ESG(Environmental, Social and Governance) Assessment USL-supplierquestionnaire Bora Pharmaceuticals to Sponsor “Berkeley Dialogue” in Taipei, Advancing the Biopharma R&D and Supply Chain 資訊安全管理 Risk Management 風險管理 Internal Policies 重要內規 保瑞藥業將與加州大學柏克萊分校攜手舉辦「與柏克萊對話」，倡議生技製藥研發與供應鏈韌性 Talent Attraction and Retention Social Care Climate and Energy Management supplierquestionnaire 董事會 誠信經營 Board of Directors Compliance and Integrity Management Stakeholder Communication 企業永續發展自評表 ESG(Environmental, Social and Governance) Assessment 利害關係人專區 Bora Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% test2 保瑞公告Cyclosporine 眼用乳劑0.05%美國取證 Intellectual Property Home